Jobs with high IPF mortality ratios differed by sex, but notable categories for both included the public administration industry and health care practitioners and technical occupations, according to ...

The company’s focus will be on progressing the clinical validation of its idiopathic pulmonary fibrosis treatment.

Idiopathic pulmonary fibrosis is a progressive and life-threatening lung disease but there are ASX companies bringing hope to ...

According to a recent study, roughly one in five of idiopathic pulmonary fibrosis deaths might be related to occupational exposures.

Pliant Therapeutics ends its Phase 2b IPF trial for bexotegrast, prompting a Needham downgrade to Hold due to limited ...

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the ...

Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...

Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their ...

The following is a summary of "Supplemental oxygen therapy use among patients with fibrosing interstitial lung disease in the United States," published in the February 2025 issue of the Respiratory ...

Pliant Therapeutics (PLRX) announced that following a prespecified data review and recommendation by the trial’s independent Data Safety ...